Dr Brian Chambers and colleagues at the Austin Hospital, Melbourne, have published further findings from their MS Research

An international team of scientists including a strong Australian contingent has made a key discovery in new research

A landmark genetics paper published today has identified 48 new genes involved in the risk of developing MS.

The European Medicines Agency yesterday approved alemtuzumab (Lemtrada) for relapsing remitting MS. Alemtuzumab is an intravenous infusion drug

Researchers have used proteomic profiling to characterise stages and severity of MS, in an attempt to provide new

Recent months have seen further publication of the findings from ongoing research into chronic cerebrospinal venous insufficiency (CCSVI)

The USA Federal Drug Administration (FDA) is investigating a case of progressive multifocal leukoencephalopathy (PML) in a 46

Multiple Sclerosis Research Australia has welcomed the recent Pharmaceutical Benefits Advisory Committee (PBAC) recommendations for two new oral

ANZgene, the consortium of MS genetics researchers across Australia and New Zealand, supported by MS Research Australia, has